gemcitabine + nab-paclitaxel + lenvatinib + tislelizumab

This is a combination regimen consisting of four distinct pharmaceutical agents: **gemcitabine**, **nab-paclitaxel** (nanoparticle albumin-bound paclitaxel), **lenvatinib**, and **tislelizumab**. - **Gemcitabine** is a nucleoside analog that inhibits DNA synthesis, causing cell death in rapidly dividing cells. - **Nab-paclitaxel** is a nanoparticle albumin-bound formulation of paclitaxel, a microtubule inhibitor that disrupts mitosis in cancer cells[1][6]. - **Lenvatinib** is a multi-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT, inhibiting angiogenesis and tumor growth. - **Tislelizumab** is a humanized IgG4 monoclonal antibody against programmed death-1 (PD-1), acting as an immune checkpoint inhibitor to enhance anti-tumor immunity. This combination is under investigation for potential use in advanced solid tumors, particularly pancreatic cancer, reflecting a strategy that combines cytotoxic chemotherapy, targeted anti-angiogenic therapy, and immunotherapy to potentially improve tumor response rates over standard regimens[7].

Other names

Gemcitabine, nab-Paclitaxel, Lenvatinib, and Tislelizumab quadruplet regimenGALENT-BT regimen